Table 2. Association of clinical stages of lung cancer with ThinPrep.
| Stage | N (%) | ThinPrep (% of positive cases) | P value |
| Ia | 19 (8.5) | 84.2 | |
| Ib | 55 (24.7) | 87.3 | |
| IIa | 32 (14.3) | 90.6 | |
| IIb | 47(21.1) | 93.6 | |
| IIIa | 36 (16.1) | 86.1 | |
| IIIb | 24 (10.8) | 83.3 | |
| IV | 10 (4.5) | 70 | |
| Total | 223 (100) | 0.505 | |
| Ia | 0 (0) | 0 | |
| Ib | 7 (9.1) | 42.9 | |
| IIa | 2 (2.6) | 50 | |
| IIb | 9 (11.7) | 44.4 | |
| IIIa | 23 (29.9) | 60.9 | |
| IIIb | 17 (22.1) | 70.6 | |
| IV | 19 (24.7) | 68.4 | |
| Total | 77 (100) | 0.668 | |
| Limited | 89 (58.6) | 68.6 | |
| Extensive | 63 (41.4) | 52.4 | |
| Total | 152 (100) |
SCC, squamous cell carcinoma; ADC, adenocarcinoma; SCLC, small cell lung carcinoma.